The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1140
September 30, 2002
View Complete Issue         Table of Contents 2019 
Escitalopram (Lexapro) for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Escitalopram (Lexapro) for Depression
September 30, 2002 (Issue: 1140)
Escitalopram (Lexapro - Forest), the active S-enantiomer of racemic citalopram (Celexa - Forest), a selective serotonin reuptake inhibitor (SSRI), was recently approved by the FDA for treatment of depression. The manufacturer plans to stop promoting...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Escitalopram (Lexapro) for Depression
Article code: 1140a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.